Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
Renal drug transporters and their significance in drug-drug interactions.

Acta pharmaceutica Sinica. B

Yin J, Wang J.
PMID: 27709005
Acta Pharm Sin B. 2016 Sep;6(5):363-373. doi: 10.1016/j.apsb.2016.07.013. Epub 2016 Aug 09.

The kidney is a vital organ for the elimination of therapeutic drugs and their metabolites. Renal drug transporters, which are primarily located in the renal proximal tubules, play an important role in tubular secretion and reabsorption of drug molecules...

Cite
Yin J, Wang J. Renal drug transporters and their significance in drug-drug interactions. Acta Pharm Sin B. 2016;6(5):363-373doi: 10.1016/j.apsb.2016.07.013.
Yin, J., & Wang, J. (2016). Renal drug transporters and their significance in drug-drug interactions. Acta pharmaceutica Sinica. B, 6(5), 363-373. https://doi.org/10.1016/j.apsb.2016.07.013
Yin, Jia, and Wang, Joanne. "Renal drug transporters and their significance in drug-drug interactions." Acta pharmaceutica Sinica. B vol. 6,5 (2016): 363-373. doi: https://doi.org/10.1016/j.apsb.2016.07.013
Yin J, Wang J. Renal drug transporters and their significance in drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):363-373. doi: 10.1016/j.apsb.2016.07.013. Epub 2016 Aug 09. PMID: 27709005; PMCID: PMC5045553.
Copy Download .nbib Format: NLM
Targeting uptake transporters for cancer imaging and treatment.

Acta pharmaceutica Sinica. B

Zhang Y, Wang J.
PMID: 31993308
Acta Pharm Sin B. 2020 Jan;10(1):79-90. doi: 10.1016/j.apsb.2019.12.005. Epub 2019 Dec 16.

Cancer cells reprogram their gene expression to promote growth, survival, proliferation, and invasiveness. The unique expression of certain uptake transporters in cancers and their innate function to concentrate small molecular substrates in cells make them ideal targets for selective...

Cite
Zhang Y, Wang J. Targeting uptake transporters for cancer imaging and treatment. Acta Pharm Sin B. 2019;10(1):79-90doi: 10.1016/j.apsb.2019.12.005.
Zhang, Y., & Wang, J. (2020). Targeting uptake transporters for cancer imaging and treatment. Acta pharmaceutica Sinica. B, 10(1), 79-90. https://doi.org/10.1016/j.apsb.2019.12.005
Zhang, Yuchen, and Wang, Joanne. "Targeting uptake transporters for cancer imaging and treatment." Acta pharmaceutica Sinica. B vol. 10,1 (2020): 79-90. doi: https://doi.org/10.1016/j.apsb.2019.12.005
Zhang Y, Wang J. Targeting uptake transporters for cancer imaging and treatment. Acta Pharm Sin B. 2020 Jan;10(1):79-90. doi: 10.1016/j.apsb.2019.12.005. Epub 2019 Dec 16. PMID: 31993308; PMCID: PMC6977162.
Copy Download .nbib Format: NLM
Development and validation of a LC-MS/MS method for in vivo quantification of meta-iodobenzylguanidine (mIBG).

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

López Quiñones AJ, Shireman LM, Wang J.
PMID: 34530306
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Sep 01;1181:122927. doi: 10.1016/j.jchromb.2021.122927. Epub 2021 Sep 03.

meta-iodobenzylguanidine (mIBG) is a radiopharmaceutical used for the diagnosis and treatment of neuroendocrine cancers. Previous quantification of mIBG in biodistribution and pharmacokinetic studies mainly relied on the use of radiolabeled mIBG, which involves the handling of highly radioactive materials....

Cite
López Quiñones AJ, Shireman LM, Wang J. Development and validation of a LC-MS/MS method for in vivo quantification of meta-iodobenzylguanidine (mIBG). J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1181:122927doi: 10.1016/j.jchromb.2021.122927.
López Quiñones, A. J., Shireman, L. M., & Wang, J. (2021). Development and validation of a LC-MS/MS method for in vivo quantification of meta-iodobenzylguanidine (mIBG). Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1181122927. https://doi.org/10.1016/j.jchromb.2021.122927
López Quiñones, Antonio J, et al. "Development and validation of a LC-MS/MS method for in vivo quantification of meta-iodobenzylguanidine (mIBG)." Journal of chromatography. B, Analytical technologies in the biomedical and life sciences vol. 1181 (2021): 122927. doi: https://doi.org/10.1016/j.jchromb.2021.122927
López Quiñones AJ, Shireman LM, Wang J. Development and validation of a LC-MS/MS method for in vivo quantification of meta-iodobenzylguanidine (mIBG). J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Sep 01;1181:122927. doi: 10.1016/j.jchromb.2021.122927. Epub 2021 Sep 03. PMID: 34530306; PMCID: PMC8545618.
Copy Download .nbib Format: NLM
Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene.

Molecular autism

Adamsen D, Ramaekers V, Ho HT, Britschgi C, Rüfenacht V, Meili D, Bobrowski E, Philippe P, Nava C, Van Maldergem L, Bruggmann R, Walitza S, Wang J, Grünblatt E, Thöny B.
PMID: 25802735
Mol Autism. 2014 Aug 13;5:43. doi: 10.1186/2040-2392-5-43. eCollection 2014.

BACKGROUND: Patients with autism spectrum disorder (ASD) may have low brain serotonin concentrations as reflected by the serotonin end-metabolite 5-hydroxyindolacetic acid (5HIAA) in cerebrospinal fluid (CSF).METHODS: We sequenced the candidate genes SLC6A4 (SERT), SLC29A4 (PMAT), and GCHFR (GFRP), followed...

Cite
Adamsen D, Ramaekers V, Ho HT, et al. Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene. Mol Autism. 2014;5:43doi: 10.1186/2040-2392-5-43.
Adamsen, D., Ramaekers, V., Ho, H. T., Britschgi, C., Rüfenacht, V., Meili, D., Bobrowski, E., Philippe, P., Nava, C., Van Maldergem, L., Bruggmann, R., Walitza, S., Wang, J., Grünblatt, E., & Thöny, B. (2014). Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene. Molecular autism, 543. https://doi.org/10.1186/2040-2392-5-43
Adamsen, Dea, et al. "Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene." Molecular autism vol. 5 (2014): 43. doi: https://doi.org/10.1186/2040-2392-5-43
Adamsen D, Ramaekers V, Ho HT, Britschgi C, Rüfenacht V, Meili D, Bobrowski E, Philippe P, Nava C, Van Maldergem L, Bruggmann R, Walitza S, Wang J, Grünblatt E, Thöny B. Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene. Mol Autism. 2014 Aug 13;5:43. doi: 10.1186/2040-2392-5-43. eCollection 2014. PMID: 25802735; PMCID: PMC4370364.
Copy Download .nbib Format: NLM
Expression Profiling of Solute Carrier Gene Families at the Blood-CSF Barrier.

Frontiers in pharmacology

Ho HT, Dahlin A, Wang J.
PMID: 22936914
Front Pharmacol. 2012 Aug 24;3:154. doi: 10.3389/fphar.2012.00154. eCollection 2012.

The choroid plexus (CP) is a highly vascularized tissue in the brain ventricles and acts as the blood-cerebrospinal fluid (CSF) barrier (BCSFB). A main function of the CP is to secrete CSF, which is accomplished by active transport of...

Cite
Ho HT, Dahlin A, Wang J. Expression Profiling of Solute Carrier Gene Families at the Blood-CSF Barrier. Front Pharmacol. 2012;3:154doi: 10.3389/fphar.2012.00154.
Ho, H. T., Dahlin, A., & Wang, J. (2012). Expression Profiling of Solute Carrier Gene Families at the Blood-CSF Barrier. Frontiers in pharmacology, 3154. https://doi.org/10.3389/fphar.2012.00154
Ho, Horace T B, et al. "Expression Profiling of Solute Carrier Gene Families at the Blood-CSF Barrier." Frontiers in pharmacology vol. 3 (2012): 154. doi: https://doi.org/10.3389/fphar.2012.00154
Ho HT, Dahlin A, Wang J. Expression Profiling of Solute Carrier Gene Families at the Blood-CSF Barrier. Front Pharmacol. 2012 Aug 24;3:154. doi: 10.3389/fphar.2012.00154. eCollection 2012. PMID: 22936914; PMCID: PMC3426838.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries